LETTER TO THE EDITOR
|Year : 2020 | Volume
| Issue : 6 | Page : 825-826
Two clinical cases of LBSL: Diagnostic problems and possible therapeutic approaches
Mariia A Bedova1, Aleksandr G Ilves2, Lidia N Prakhova2, Zhanna I Savintseva2, Elena M Chernysheva2
1 Pediatric Research and Clinical Center for Infectious Diseases, 197022, Prof. Popov Str., 9, Saint-Petersburg, Russia
2 N.P. Bechtereva Institute of the Human Brain of the Russian Academy of Sciences, 197376, Akad. Pavlov Str., 12A, Saint-Petersburg, Russia
|Date of Submission||22-Aug-2019|
|Date of Decision||21-Sep-2019|
|Date of Acceptance||06-Oct-2019|
|Date of Web Publication||26-Nov-2019|
Dr. Mariia A Bedova
197022, Prof. Popov Str., 9, Saint-Petersburg
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Bedova MA, Ilves AG, Prakhova LN, Savintseva ZI, Chernysheva EM. Two clinical cases of LBSL: Diagnostic problems and possible therapeutic approaches. Ann Indian Acad Neurol 2020;23:825-6
|How to cite this URL:|
Bedova MA, Ilves AG, Prakhova LN, Savintseva ZI, Chernysheva EM. Two clinical cases of LBSL: Diagnostic problems and possible therapeutic approaches. Ann Indian Acad Neurol [serial online] 2020 [cited 2021 Jan 17];23:825-6. Available from: https://www.annalsofian.org/text.asp?2020/23/6/825/271740
Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) is a rare autosomal-recessive disease which is first described by Marjo van der Knaap in 2003. Currently, there are less than 200 clinical cases of LBSL presented in the literature. LBSL is caused by mutations in the DARS2 gene that encodes the mitochondrial aspartyl-tRNA synthetase. Decrease in the activity of mitochondrial aspartil-tRNA synthetase leads to the non-inclusion of aspartic acid residue in the structure of all mitochondrial proteins and to the disruption of redox processes in the cell, as well as to the activation of the histotoxic hypoxia mechanism.
Magnetic resonance imaging (MRI) features of LBSL are very characteristic and allow to establish a preliminary diagnosis before genetic examination. The disease is characterized by slowly progressive pyramidal disorders, ataxia and decreased proprioception. No specific LBSL therapy has been developed. Based on the pathogenesis, therapy may include the use of antioxidants and antihypoxants.
We observed 2 patients with the late onset of LBSL who, despite the MRI findings, were initially misdiagnosed as having multiple sclerosis (MS). After the correct diagnosis, the patients were treated with the derivatives of succinic acid with good clinical effect.
| Case 1|| |
A 31-year-old woman was hospitalized in our clinic with complaints about shaky gait, intermittent numbness and burning in her legs. Neurological status: Pathological upper limb and plantar signs, muscle fatigue, hypoesthesia in the right shin, lack of vibration sense in the legs, intention tremor, ataxia in the Romberg's test were noted.
At the age of 30, she noticed pain in her right thigh, then, progressive weakness and numbness in her legs, unsteady gait, and non-systemic dizziness. MRI revealed symmetrical multifocal lesions in the brain and spinal cord without contrast enhancement [Figure 1]. The patient was diagnosed with MS. Pulse therapy with methylprednisolone (MP) and IVIg were ineffective. The diagnosis of LBSL was suggested, and the results of the examination revealed a heterozygous mutant gene DARS2.
|Figure 1: Axial T2-WI of the brain demonstrates symmetrical white matter lesions involving periventricular white matter (a), intraparenchymal trajectory of the trigeminal nerve (b), anterior part of the medulla oblongata (c), dorsal and lateral parts of the spinal cord (d)|
Click here to view
Considering the fact that one of the main components of LBSL pathogenesis is a decrease in the activity of mitochondrial aspartyl-tRNA synthetase and an insufficiency of mitochondrial protein functioning, which, in turn, leads to a disruption of redox processes in the cells, the patient was treated with a succinic acid derivative - Ethylmethylhydroxypyridine Succinate (EMHS) 15 days, 1000 mg intravenously (IV) daily.
After the EMHC therapy, numbness and burning sensation regressed in the legs. Intention tremor and the instability in the Romberg's test decreased. The patient continued with an ongoing maintenance therapy with EMHS per os at a daily dose of 750 mg after discharge from the hospital. She received the same EMHS infusion courses every 6 months. Neurological status and MRI pattern upon the follow-up examination after a year were stable.
| Case 2|| |
A 27-year-old woman was referred to our clinic concerning unsteady walk, weakness in the right leg, which appeared and developed over the course of two years. MRI of the brain was performed at the place of residence, which resulted in the diagnosis MS. MP was administered without effect.
MRI study revealed a longitudinally extensive dorso-lateral spinal cord lesion involving almost the entire cord. A heterozygous DARS2 mutant gene was detected during the genetic study (a mutation affecting the CS0722183 c.492 + 2T > C splicing site and the CX072638 c.228-20_21delTTinsC mutation). A diagnosis of LBSL was established.
As in the previous clinical case, the patient was treated by the same therapeutic regimen EMHS with the following results: Decrease ataxia, increase in strength in the legs. Patient's condition remains stable according to the follow-up MRI and neurological examination data after one year of therapy.
| Discussion|| |
These clinical cases demonstrate the difficulty of diagnosing LBSL. This is associated with the rarity of LBSL occurrence and the lack of awareness among radiologists and neurologists.
Considering the absence of drugs with proven efficacy, it is necessary to find ways to influence the main pathogenetic components of LBSL. It is known that the majority of patients with this disease are DARS2 compound heterozygous carriers of mutation, and one of the mutations almost always affects the splicing site in intron 2, above exon 3, so exon 3 is not included in the transport RNA, which may lead to a shift in the reading frame, premature stop of protein synthesis or lack of functional protein. However, mutations of the intron 2 splicing site in LBSL result in partial disruption of translation, and a full-size functional protein is synthesized from a part of the mutated tRNA, and this, in turn, leads to a slowdown of energy processes in the cell, but not to their complete stoppage. We used EMHS as a pathogenetic therapy agent with antioxidant and membranotropic effect. The 3-hydroxypyridine molecule reduces glutamate excitotoxicity, modulates the functioning of receptors and membrane-linked enzymes, and restores the neurotransmitter balance. EMHC influences free radical processes (inhibits lipid peroxidation, reacts with primary and hydroxyl radicals of peptides, reduces the increased level of NO in the brain in pathological conditions), at the same time increases the activity of antioxidant enzymes (including superoxide dismutase, glutathione peroxidase) and has no prooxidant effect. The presence of succinate in the structure of EMHC, which is able to oxidize the respiratory chain in conditions of hypoxia, leads to an increase in the compensatory activation of aerobic glycolysis, a decrease in the oppression of oxidative processes in the Krebs cycle, and thus to an increase in the content of ATP, creatine phosphate, activation of energy-synthetic functions of mitochondria.
In both cases, there was a positive effect in the reduction of cerebellar abnormalities, sensory and pyramidal disorders, which may be due to increased functional activity of enzymes, inclusion of succinate as a substrate in the respiratory chain and activation of energy metabolism, inhibition of free-radical processes in cells of the brain and spinal cord in a histotoxic hypoxia.
Our observations may indicate that the use of drugs with the mechanism of action described above may be promising in this group of patients, but it is necessary to conduct further controlled studies.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Van der Knaap MS, Van der Voorn P, Barkhof F, Van Coster R, Krageloh-Mann I, Feigenbaum A. A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol 2003;53:252-8.
Scheper GC, Van der Klok T, Van Andel RJ, Van Berkel CG, Sissler M, Smet J, et al
. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet 2007;39:534-9.
Van Berge L, Hamilton EM, Linnankivi T. Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: Clinical and genetic characterization and target for therapy. Brain 2014;137:1019-29.
Kassem H, Wafaie A, Abdelfattah S. Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL): Assessment of the involved white matter tracts by MRI. Eur J Radiol 2014;83:191-6.
Yelam A. Leucoencephalopathy with brain stem and spinal cord involvement and lactate elevation: A novel mutation in the DARS2 gene. BMJ Case Rep 2019:12: 292-6.
Voronina TA. Mexidol: Spectrum of pharmacological effects. J Neurol Neurosurg 2012;12:86-90.